AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology Read more
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa Read more
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI (lifileucel) for Advanced Melanoma Read more
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing Read more
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review Read more
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 Read more
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy Read more
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication Read more
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer Read more
Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology Read more